http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Acute Pancreatitis Induced by Methimazole Treatment in a 51-Year-Old Korean Man: A Case Report
정정화,함종렬,정태식,김수경,김성수,김경영,김보라,김홍준,정이영,김선주 대한의학회 2014 Journal of Korean medical science Vol.29 No.8
Methimazole (MMI)-induced acute pancreatitis is very rare but severe adverse reaction. A51-yr-old male developed a high fever, chills, and abdominal pain, two weeks aftercommencement on MMI for the treatment of Graves’ disease. There was no evidence ofagranulocytosis, and fever subsided soon after stopping MMI treatment. However, 5 hrafter taking an additional dose of MMI, abdominal pain and fever developed again. Hissymptoms, biochemical, and imaging studies were compatible with acute pancreatitis. After withdrawal of MMI, he showed clinical improvement. This is the first case of MMIinducedacute pancreatitis in Korea. Clinicians should be aware of the rare but possibleMMI-induced pancreatitis in patients complaining of fever and abdominal pain.
축구선수의 Detraining과 Retraining이 혈청지질 및 호르몬농도에 미치는 영향
정정화,박재현,채종훈,성혜련,황지인,윤미숙,노금선,윤종관,윤영학,노순덕,정경숙,박일규,김은희,박현태,박상갑 대한스포츠의학회 1999 대한스포츠의학회지 Vol.17 No.1
The purpose of this study was to investigate the effects of detraining and retraining on serum lipid and hormones in soccer players. Subjects were seven male high-school soccer players. V˙O_2max was determined for each subjects by administering a treadmill test(initial speed: 90m/min, grade: 5%, increasing speed per 3 min: 30m/min). Serum lipid(T-C, TG, HDL-C LDL-C) and hormones(epinephrine, norepinephrine, growth hormones, cortisol) were assayed pre and post detraining in 10, 20, 30 days after retraining. The repeated ANOVA was used to determine significant differences. The 0.05 level of significance was as critical level for the study. The results of the study were as follows: 1. V˙O_2max(ml/min) were 3576.3±204.2ml/min pre detraining, 3234.1±198.9 ml/min post detraining. There are significant(p<.05) difference between pre and post detraining. In 10, 20, 30 days after retraining, V˙O_2max(ml/min) were 3601.4±170.9 ml/min. There were significantly(p<.05) increased in retraining periods. 2. V˙O_2max(ml/kg/min) were significantly(p<.05) decreased from 62.3±2.9 ml/kg/min to 55.9±4.7 ml/kg/min in detraining. In 10, 20, 30 days after retraining, V˙O_2max(ml/kg/min) were 62.4±3.4ml/kg/min, 62.7±2.3ml.kg/min, 67.3±7.2ml/kg/min respectively. There were significantly(p<.05) increased in retraining periods. 3. T-C were significantly (p<.05) increased from 166.6±8.5mg/dl to 175.3±10.3 mg/dl in detraining. In 10, 20, 30 days after retraining, T-C were 160.1± 3.2mg/dl, 156.7±3.7mg/dl, 140.3±9.0mg/dl. There were significantly(p<.05) decreased in retraining periods. 4. HDL-C were 61.4±6.6mg/di pre detraining, 5.3±6.6mg/dl post detraining. There are significant(p<.05) difference between pre and post detraining. In 10, 20, 30 days after retraining, HDL-C were 56.9±7.1mg/dl, 56.4±9.2mg/dl, 57.7±9.1mg/dl respectively. There were no significant difference in retraining periods. 5. The hormones(epinephrine. norepinephrine, growth hormone, cortisol) were changed as same patterns. Epinephrine were 26.0±7.0[g/ml pre detraining, 24.6±3.2pg/ml post detraining. In 10, 20, 30 days after retraining, epinephrine were 26.9±5.6pg/ml, 30.6±6.2pg/ml, 29.4±5.6pg/ml respectively. There were no significant difference in retraining periods. In conclusion, HDL-C, epinephrine, norepinephrine, growth hormone and cortisol were decreased, T-C, LDL-C and TG were increased in detraining. But HDL-C, epinephrine, norepinephrine, growth hormone and cortisol were increased, T-C, LDL-C and TG were decreased in retraining.
정정화,김근숙,정태식,오영륜,장혜원,정혜승,민용기,이명식,이문규,김광원,정재훈 대한내분비학회 2007 Endocrinology and metabolism Vol.22 No.3
Background: RET/PTC rearrangement and mutations of BRAF and ras are well-known oncogenes involved in the pathogenesis of papillary thyroid carcinoma (PTC). The prevalence of RET/PTC rearrangement and BRAF mutations were 0~13% and 66~83% in Korean patients with PTC, respectively. We evaluated the prevalence of ras mutations in surgical specimens of PTC, and we compared them with the patients' clinical features.Subjects and Methods: We included the surgical specimens of 49 PTCs and a few follicular thyroid carcinomas (FTCs) and follicular adenomas (FAs) as positive controls. Polymerase chain reaction, single strand conformation polymorphism and direct sequence analysis were consecutively performed to detect ras mutations.Results: No mutations of the ras oncogenes were detected in 49 PTCs. However, heterozygous mutations of the ras oncogenes were found in a FTC and FA as positive controls, respectively. Conclusion: These findings suggested that ras mutation is not or rarely related to the tumorigenesis of PTCs in Koreans. Therefore, BRAF mutations and RET/PTC rearrangement, rather than ras mutation, might contribute the development of PTC in Koreans. (J Kor Endocrine Soc 22:203~209, 2007) 연구배경: RET/PTC 재배열 및 BRAF와 ras 변이는 갑상선 유두암의 발병기전에 잘 알려져 있는 암유전자이다. 한국인의 갑상선 유두암에서 RET/PTC 재배열과 BRAF 변이의 비율은 각각 0~12.9%와 66~83%을 차지한다. 본 연구에서는 한국인 갑상선 유두암에서 ras 변이의 빈도를 조사하여 ras 변이가 유두암 발생에 기여하는 정도를 알아보고자 하였다.방법: 갑상선 유두암으로 진단된 49예의 조직을 대상으로 하였고 양성 대조군으로 갑상선 여포암과 양성 여포종양 조직을 사용하였다. ras 변이 검색을 위해 중합효소연쇄반응과 Single strand conformation polymorphism (SSCP), 유전자 염기서열 분석을 차례로 시행하였다.결과: 49예의 갑상선 유두암 조직에서 K-, N-, 그리고 H-ras의 변이는 관찰되지 않았다. 그러나 양성 대조군으로 사용한 갑상선 여포암과 양성 여포종양 조직에서는 이형접합체 변이를 관찰할 수 있었다.
Current Antiplatelet Treatment Strategy in Patients with Diabetes Mellitus
정정화,Udaya S. Tantry,Paul A. Gurbel,정영훈 대한당뇨병학회 2015 Diabetes and Metabolism Journal Vol.39 No.2
Patients with diabetes mellitus (DM) have accelerated atherosclerosis with an increased risk for atherothrombotic cardiovascular complications. A state of high platelet reactivity and activation, hypercoagulability (prothrombotic state) and a subdued response to standard antiplatelet agents may explain high rate of adverse cardiovascular events in patients with DM. Several antithrombotic treatment strategies have been developed to control the prothrombotic state in patients with DM: dose modification of commonly used agents; use of potent agents; and addition of a third antithrombotic drug (triple therapy) to commonly prescribed dual antiplatelet therapy of aspirin and a P2Y12 inhibitor. The present review aims to provide an overview of the current knowledge on platelet abnormalities in patients with DM, focusing on the challenges and perspectives of antiplatelet treatment strategies in this population.